Document:

EX-10.22

 Exhibit 10.22 

 
 

 
 CONSULTING AGREEMENT 

THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of
June 27, 2012 (the “Effective Date”) by and between METABOLEX, INC., a Delaware corporation located at 3876 Bay Center Place, Hayward, California 94545
(“Metabolex”), and SNPLIVE, LLC, a company with a mailing address at 5086 Holborn Way, San Ramon, CA 94582 (“Consultant”). 
 IN CONSIDERATION of the mutual obligations set forth below, the parties hereby agree as follows: 

1. PERFORMANCE OF SERVICES. Consultant shall provide consulting
services to Metabolex (the “Services”) in the field of fundraising and related financial services (the “Field”). Consultant shall render the Services at such times as may be mutually agreed upon by Consultant and
Metabolex and at a minimum of two days per week. Consultant shall perform the Services at Metabolex’s principal place of business, another Metabolex location, or at other places upon mutual agreement of the parties. Consultant shall perform the
Services in a timely and professional manner consistent with industry standards, and shall comply with all applicable laws and regulations in performing the Services. 
 2. COMPENSATION. Metabolex shall pay Consultant the compensation listed in Exhibit A for performing Services requested by Metabolex. Consultant will
provide Metabolex, on a monthly basis, itemized invoices detailing the amount and type of Services provided by Consultant during the applicable month. All payments due to Consultant under this Agreement will be made by Metabolex within 30 days of
receipt of a proper invoice therefor. Metabolex shall also reimburse Consultant for out-of-pocket expenses incurred by Consultant in performing the Services, provided that such expenses are supported by written receipts and are reasonable and
necessary as determined by Metabolex. In no event shall Metabolex be required to reimburse Consultant with respect to general, administrative or other overhead expenses. Travel expenses must be approved by Metabolex in advance. 

3. MAINTAINING CONFIDENTIAL INFORMATION 

3.1 Confidential Information. During the term of this Agreement and in the course of Consultant’s performance hereunder,
Consultant may receive or otherwise be exposed to confidential and/or proprietary information relating to Metabolex’s technology, know-how, data, inventions, developments, plans, business practices, and strategies (collectively referred to as
“Confidential Information”). Confidential Information may include, without limitation, the following: (i) business or technical information concerning research, development, commercial plans and strategies, experimental work,
design details and specifications, business operations and systems, marketing techniques, marketing plans, material pricing policies, financial information, procurement requirements, purchasing, manufacturing, customer lists, investors, employees,
business and contractual relationships, business forecasts, sales and merchandising, customers, licensees, vendors, clinical development strategies, and scientific evaluations, and (ii) any patent, patent application, trade secret, invention,
idea, procedure, formulation, process, formula, chemical compound, biological material, assay, or data. Without limiting the foregoing in any way, all information disclosed by Metabolex to Consultant that is related to the Field shall be considered
Confidential Information. 

 3.2 Non-Disclosure and Non-Use of Confidential Information. All Confidential
Information is the sole and exclusive property of Metabolex. Consultant shall not reproduce any Confidential Information without the prior written consent of Metabolex, shall not use Confidential Information except in the performance of the
Services, and shall not to disclose all or any part of the Confidential Information in any form to any third party. In particular, Consultant shall not file any patent application containing any claim the subject matter of which is derived from
Confidential Information. 
 3.3 Protection of Confidential Information. Consultant shall take security precautions equal
to or greater than those security precautions Consultant employs to protect Consultant’s own highly confidential information, but in any event not less than reasonable security precautions, to protect from disclosure and to keep confidential
the Confidential Information, including without limitation, protection of documents from theft, unauthorized duplication and discovery of contents, and restrictions on access by other persons to Confidential Information. Consultant may make a
limited disclosure of such Confidential Information as Consultant may be required to disclose by law, government regulation or court order; provided, however, that in any such event, Consultant will give Metabolex at least 30 days advance
notice so that Metabolex may seek a protective order or take other action reasonable in light of the circumstances to prevent and/or limit the scope of any such disclosure. 
 3.4 Exceptions to Confidential Information. Confidential Information shall not be deemed to include information that: (a) is now, or hereafter becomes, through no act or failure to act on the
part of Consultant, generally known or available; (b) is known by Consultant at the time of receiving such information as evidenced by his or her written records; (c) is hereafter furnished to Consultant by a third party, as a matter of
right and without restriction on disclosure; or (d) is the subject of a written permission to disclose provided by Metabolex. For clarity, it is understood that notwithstanding the fact that individual components of information are in the
public domain, but a particular compilation or integration of such components is not in the public domain, the fact that such individual components are in the public domain does not relieve the Consultant of its obligations of confidentiality under
this Section 3.4 with regard to the compilation or integration of such components. 
 3.5 Third Party Information.
During the term of this Agreement, Consultant agrees to properly protect any proprietary information or trade secrets of Consultant’s former or concurrent employers or companies, if any, and agrees not to bring onto the premises of
Metabolex any unpublished documents or any property belonging to Consultant’s former or concurrent employers or companies unless consented to in writing by those employers or companies. Consultant further recognizes that Metabolex has received
and in the future will receive from third parties their confidential or proprietary information subject to a duty on Metabolex’s part to maintain the confidentiality of such information and, in some cases, to use it only for certain limited
purposes. Consultant agrees, both during the term of Consultant’s engagement and thereafter, to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation (except
in a manner that is consistent with Metabolex’s agreement with the third party) or use it for the benefit of anyone other than Metabolex or such third party (consistent with Metabolex’s agreement with the third party). 

3.6 Term of Confidentiality Obligations. Consultant’s obligations of non-disclosure, non-use and protection of Confidential
Information will survive termination of this Agreement and will be binding upon Consultant for five years after the Effective Date. 

  
 2 

 4. INVENTIONS 

4.1 Disclosure of Inventions. Consultant shall promptly and fully disclose to Metabolex any and all ideas, improvements,
inventions, know-how, techniques, and works of authorship learned, conceived, or developed by Consultant, either alone or jointly with others, pursuant to the performance of the Services or that result from the use of equipment or premises owned or
leased by Metabolex (the “Inventions”). Consultant agrees to keep and maintain adequate and current records (in the form of notes, sketches, drawings or in any other form that may be required by Metabolex) of all work performed
relating to the Services, including all proprietary information developed relating thereto, and such records shall be available to and remain the sole property of Metabolex at all times. 

4.2 Ownership of Inventions. Consultant agrees that any and all Inventions shall be the sole and exclusive property of Metabolex.
Consultant hereby assigns to Metabolex all his or her right, title, and interest in and to any and all Inventions. Consultant further agrees that Metabolex is and shall be vested with all rights, title, and interest, including patent, copyright,
trade secret, and trademark rights, in and to all of Consultant’s Inventions under this Agreement. 
 4.3 Perfecting
Proprietary Rights. Consultant agrees to assist Metabolex in every proper way to obtain and enforce United States and foreign proprietary rights relating to the proprietary rights (including Inventions) in any and all countries. To that end,
Consultant agrees to execute, verify and deliver such documents and perform such other acts (including appearing as a witness) as Metabolex may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining, and enforcing
such proprietary rights and the assignment thereof. In addition, Consultant agrees to execute, verify, and deliver assignments of such proprietary rights to Metabolex or its designee. Consultant’s obligation to assist Metabolex with respect to
proprietary rights in any and all countries shall continue beyond the termination of the Agreement, but Metabolex shall compensate Consultant at a reasonable rate after such termination for the time actually spent by Consultant at Metabolex’s
request on such assistance. 
 4.4 Designation of Attorney in Fact. In the event Metabolex is unable for any reason,
after reasonable effort, to secure Consultant’s signature on any document needed in connection with the actions specified in Section 4.3, Consultant hereby irrevocably designates and appoints Metabolex and its duly authorized officers and
agents as Consultant’s agent and attorney in fact to execute, verify and file, with the same legal force and effect as if executed by Consultant, any such documents and to do all other lawfully permitted acts to further the purposes of the
preceding paragraph. Consultant hereby waives and quitclaims to Metabolex any and all claims of any nature whatsoever that Consultant now or may hereafter have for infringement of any proprietary rights assigned to Metabolex. 

5. COMPLIANCE WITH LAWS AND COMPANY
POLICIES 
 5.1 Compliance with Laws. Consultant agrees to abide by all applicable laws
related to performance of Services. 
 5.2 Compliance with Company Policies. If, at any time, Consultant is required to
work at any of Metabolex’s premises or use any of its equipment, Consultant will comply with all applicable company policies, including health and safety rules, security regulations, sexual harassment, and other instructions issued by
Metabolex, which will be made available to Consultant at such time. 

  
 3 

 6. OWNERSHIP; NO LICENSE.
Confidential Information received by Consultant and any extracts, summaries, and abstracts thereof and any developments materially derived therefrom are and shall remain the sole property of Metabolex. Nothing contained in this Agreement, nor either
party’s performance under it, shall be construed as granting Consultant any rights or licenses, express or implied, to use or disclose for any purpose whatsoever any intellectual property (including but not limited to any trade secrets,
know-how, trademarks, copyrights, and patents) or Confidential Information, owned or controlled or licensed by Metabolex. Consultant shall not perform any Services on time that Consultant is required to devote to any third party. Consultant shall
not use the funding, resources or facilities of any third party to perform the Services and shall not perform any Services in any manner that would give any third party rights to the product of such work. 

7. No CONFLICTS. Consultant represents and warrants that it is not a party to any existing agreement
that will be breached by Consultant’s performance of the Services or that conflict with the terms of this Agreement. 

8. TERM AND TERMINATION. This Agreement automatically terminates on
September 30, 2012 unless earlier terminated as provided herein or extended upon the agreement of the parties. Either party may terminate this Agreement at any time upon 30 days’ written notice. Promptly after the termination of this
Agreement, Consultant shall return to Metabolex all whole and partial copies and derivatives of Confidential Information, Inventions, and other materials belonging to Metabolex that are in Consultant’s possession or under Consultant’s
direct or indirect control. Articles 3 through 14 shall survive the termination of this Agreement. 
 9.
ASSIGNMENT. Due to the personal nature of the Services to be rendered by Consultant hereunder, Consultant may not assign this Agreement nor subcontract any of the Services to be performed under this Agreement.
Metabolex may assign all its rights and liabilities under this Agreement to any of its affiliates or to a successor to all or a substantial part of its business or assets without the consent of Consultant. Subject to the foregoing, this Agreement
will inure to the benefit of and be binding upon each of the assigns and successors of the respective parties. 
 10.
NOTICES. Any notices required or permitted under this Agreement shall be in writing and shall be delivered to the appropriate party at the address set forth herein or at such other address as the party shall specify
in writing. Such notice shall be deemed given (i) upon the date of delivery when delivered personally; (ii) upon the date such notice is transmitted by facsimile when sent by facsimile, provided that such transmission is subsequently
confirmed by telephone; (iii) one day after sending when sent by private courier service (such as Federal Express); or (iv) three days after the date of mailing when sent by certified or registered mail, postage prepaid. 

11. INDEPENDENT CONTRACTOR; CONSULTANT PERSONNEL

 11.1 INDEPENDENT CONTRACTOR. It is understood and agreed that Consultant
is an independent contractor and not an agent or employee of Metabolex, and is not authorized to act on behalf of Metabolex. Consultant agrees not to hold herself out as, or give any person any reason to believe that he or she is an employee, agent,
joint-venture partner, or other partner of Metabolex. 

  
 4 

 11.2. Consultant Personnel. Consultant will not be eligible for any employee benefits
from Metabolex, nor will Metabolex make deductions from any amounts payable to Consultant for taxes. All payroll and employment taxes and insurance, and benefits shall be the sole responsibility of Consultant. Consultant further agrees to maintain
workers’ compensation insurance in the amount required by the laws of the state in which Consultant’s employees performing the Services are located. Consultant shall provide Metabolex with a completed IRS Form W-9, including his or her
United States Tax Identification Number (TIN) upon execution of this Agreement. Metabolex shall provide Consultant with an Internal Revenue Service (IRS) Form 1099 in connection with the performance of the Services. 

12. REMEDIES. Consultant hereby acknowledges and agrees that in the event of any breach of Articles
3 or 4 of this Agreement by Consultant, including, without limitation, the actual or threatened disclosure of Confidential Information or Inventions without the prior express written consent of Metabolex, Metabolex will suffer an irreparable injury,
such that no remedy at law will afford it adequate protection against, or appropriate compensation for, such injury. Accordingly, Consultant hereby agrees that Metabolex shall be entitled to obtain equitable and such other further relief as may be
granted by a court of competent jurisdiction for such breaches, without the requirement of posting bond or other similar measures. 
 13. REPRESENTATION OF NON-DISBARMENT. Consultant warrants and represents that he or she has never been (a) debarred
or convicted of a crime for which a person can be debarred under Section 306 of the United States Food, Drug and Cosmetic Act of 1938, 21 USC § 321 (the “FDCA”) and/or any corresponding foreign laws or regulations, or
(b) threatened to be debarred or indicted for a crime or otherwise engaged in conduct for which a person can be debarred under Section 306 of FDCA and/or any corresponding foreign laws or regulations, and Consultant agrees to promptly
notify Metabolex in the event of such debarment, conviction, threat or indictment occurring during the term of this Agreement and for three years following termination of this Agreement. 

14. MISCELLANEOUS 
 14.1. ADVICE OF COUNSEL. Each party represents that it has voluntarily executed this Agreement having read and fully understood it, and
after having the opportunity to freely consult with counsel or other advisor(s) of each party’s choice, and each acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one party or the other and will be
construed accordingly. 
 14.2. SEVERABILITY. If any provision of this Agreement is found
by a proper authority to be unenforceable or invalid, such unenforceability or invalidity shall not render this Agreement unenforceable or invalid as a whole, and in such event, such provision shall be changed and interpreted so as to best
accomplish the objectives of such unenforceable or invalid provision within the limits of applicable law or applicable court decisions. 
 14.3. COUNTERPARTS. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. Copies of original signature pages sent by facsimile or pdf have the same effect as signature pages containing original signatures. 

  
 5 

 14.4. GOVERNING LAW. This Agreement is
governed by the laws of the State of California without giving effect to any choice of law principles that would require the application of the laws of a different jurisdiction. Any claim or controversy arising out of or related to this Agreement or
any breach hereof shall be submitted to a court of competent jurisdiction in or covering the County of Alameda, CA, and each party hereby consents to the exclusive jurisdiction and exclusive venue of such courts. 

14.5. ENTIRE AGREEMENT. This Agreement sets forth the entire agreement and
understanding between the parties as to its subject matter, and supersedes and cancels all prior and contemporaneous representations, understandings, agreements and discussions between the parties relating to the subject matter of this Agreement.
Each party acknowledges that in agreeing to enter into this Agreement, it has not relied on any representation, warranty or other assurance save as expressly set out in this Agreement and (except in the case of fraud) neither party shall have any
remedy against the other in the event that any such representation, warranty or assurance is found to be untrue. 
 [REMAINDER OF
PAGE INTENTIONALLY LEFT BLANK] 

  
 6 

 IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the date first above written. 
  

									
	METABOLEX, INC.	 		 	SNPLIVE, LLC
					
	By:	 	

	 		 	By:	 	

	 Name:
	 		 		 	Name:	 	SUJAL SHAH
	 Title:
	 		 		 	Title:	 	President

 FEIN or SS#: 45-    - 4928818 

  
 7 

 Exhibit A 

Compensation Formula 
  

	1.	Consultant shall be paid at a rate of 200 dollars per hour (“USD Compensation”); and 

 

	2.	Consultant agrees that Metabolex, at Metabolex’s sole discretion, may exchange up to 50 percent of consultant’s total USD Compensation for Metabolex common
stock options valued at the price set at the next financing. If a change of control transaction occurs prior to the next financing or if Metabolex chooses not to complete a financing then Consultant shall be paid 100 percent of Consultant’s
total compensation in USD. 

  
 8 

 FIRST AMENDMENT TO CONSULTING AGREEMENT 

This First Amendment (“First Amendment”) to the Consulting Agreement is entered into on September 26, 2012 (“First
Amendment Effective Date”) by Metabolex, Inc., a Delaware corporation located at 3876 Bay Center Place, Hayward, California 94545 (“Metabolex”), and SNPLive, LLC, a company with a mailing address at 5086 Holborn Way,
San Ramon, CA 94582 (“Consultant”). 
 BACKGROUND 

Metabolex and Consultant entered into the Consulting Agreement on June 27, 2012, which automatically terminates on September 30, 2012.
Metabolex wishes to continue working with Consultant and Consultant wishes to continue providing Services to Metabolex under the terms of the Consulting Agreement and this First Amendment. 
 Accordingly, Metabolex and Consultant agree as follows: 
 AMENDMENT

  

	 	1.	Term and Termination. The first sentence of Section 8 of the Consulting Agreement is hereby amended by replacing “September 30, 2012” with
“December 31, 2012.” 

 EXCEPT AS MODIFIED BY
THIS FIRST AMENDMENT, all terms of the Consulting Agreement remain unchanged, in full force and effect, and binding upon the parties hereto. 

This First Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together will constitute
one and the same instrument. Facsimile and PDF signatures have the same effect as original signatures. 
 The parties are signing this First
Amendment on the First Amendment Effective Date. 
  

									
	Metabolex, Inc.	 		 	SNPLive, LLC
					
	By:	 	

	 		 	By:	 	

	 Name:
	 	Charles A. McWherter	 		 	Name:	 	Sujal Shah
	 Title:
	 	 SVP, Research & Preclinical Development
	 		 	Title:	 	President

 SECOND AMENDMENT TO CONSULTING AGREEMENT 

This Second Amendment to the Consulting Agreement (“Second Amendment”) is entered into on December 31, 2012 (“Second
Amendment Effective Date”) by Metabolex, Inc., a Delaware corporation located at 3876 Bay Center Place, Hayward, California 94545 (“Metabolex”), and SNPLive, LLC, a company with a mailing address at 5086 Holborn Way,
San Ramon, CA 94582 (“Consultant”). 
 BACKGROUND 

Metabolex and Consultant entered into the Consulting Agreement on June 27, 2012, which automatically terminated on September 30, 2012.
Metabolex and Consultant then entered into a First Amendment to the Consulting Agreement which extended the term of the Consulting Agreement to December 31, 2012. Metabolex wishes to continue working with Consultant and Consultant wishes to
continue providing Services to Metabolex under the terms of the Consulting Agreement and this Second Amendment. 
 Accordingly, Metabolex and
Consultant agree as follows: 
 AMENDMENT 

 

	1.	Term and Termination. The first sentence of Section 8 of the Consulting Agreement is hereby amended by replacing “September 30, 2012” with
“January 31, 2013.” 

 Except as modified by this Second Amendment, all terms of the Consulting Agreement remain
unchanged, in full force and effect, and binding upon the parties hereto. 
 This Second Amendment may be executed in one or more counterparts,
each of which shall be deemed an original, but all of which together will constitute one and the same instrument. Facsimile and PDF signatures have the same effect as original signatures. 
 The parties are signing this Second Amendment on the Second Amendment Effective Date. 
  

									
	Metabolex, Inc.	 		 	SNPLive, LLC
					
	By:	 	

	 		 	By:	 	

									
	 Name:
	 	Charles A. McWherter	 		 	Name:	 	Sujal Shah

									
	 Title:
	 	 SVP, Research & Preclinical Development
	 		 	Title:	 	President

 THIRD AMENDMENT TO CONSULTING AGREEMENT 

This Third Amendment to the Consulting Agreement (“Third Amendment”) is entered into on January 29, 2012 (“Third Amendment
Effective Date”) by Metabolex, Inc., a Delaware corporation located at 3876 Bay Center Place, Hayward, California 94545 (“Metabolex”), and SNPLive, LLC, a company with a mailing address at 5086 Holborn Way, San
Ramon, CA 94582 (“Consultant”). 
 BACKGROUND 
 Metabolex and Consultant entered into the Consulting Agreement on June 27, 2012, which automatically terminated on September 30, 2012. Metabolex and Consultant then entered into (1) a First
Amendment to the Consulting Agreement which extended the term of the Consulting Agreement to December 31, 2012 and (2) a Second Amendment to the Consulting Agreement which extended the term of the Consulting Agreement to January 31,
2013. 
 Metabolex wishes to continue working with Consultant and Consultant wishes to continue providing Services to Metabolex under the terms
of the Consulting Agreement and this Third Amendment. 
 Accordingly, Metabolex and Consultant agree as follows: 

AMENDMENT 
  

	 	1.	Term and Termination. The first sentence of Section 8 of the Consulting Agreement is hereby amended by replacing “September 30, 2012” with
“March 31, 2013.” 

 Except as modified by this Third Amendment, all terms of the Consulting Agreement remain
unchanged, in full force and effect, and binding upon the parties hereto. 
 This Third Amendment may be executed in one or more counterparts,
each of which shall be deemed an original, but all of which together will constitute one and the same instrument. Facsimile and PDF signatures have the same effect as original signatures. 
 The parties are signing this Third Amendment on the Third Amendment Effective Date. 
  

									
	Metabolex, Inc.	 		 	SNPLive, LLC
					
	By:	 	

	 		 	By:	 	

									
	 Name:
	 	Charles A. McWherter	 		 	Name:	 	Sujal Shah

									
	 Title:
	 	 SVP, Research & Preclinical Development
	 		 	Title:	 	President

 FOURTH AMENDMENT TO CONSULTING AGREEMENT 

This Fourth Amendment to the Consulting Agreement (“Fourth Amendment”) is entered into on March 28,2013 (“Fourth Amendment
Effective Date”) by Metabolex, Inc., a Delaware corporation located at 3876 Bay Center Place, Hayward, California 94545 (“Metabolex”), and SNPLive, LLC, a company with a mailing address at 5086 Holborn Way, San
Ramon, CA 94582 (“Consultant”). 
 BACKGROUND 
 Metabolex and Consultant entered into the Consulting Agreement on June 27,2012, which automatically terminated on September 30, 2012. Metabolex and Consultant then entered into (1) a First
Amendment to the Consulting Agreement which extended the term of the Consulting Agreement to December 31, 2012 (2) a Second Amendment to the Consulting Agreement which extended the term of the Consulting Agreement to January 31, 2013
and (3) a Third Amendment to the Consulting Agreement which extended the term of the Consulting Agreement to March 31, 2013. 

Metabolex wishes to continue working with Consultant and Consultant wishes to continue providing Services to Metabolex under the terms of the Consulting
Agreement and this Fourth Amendment. 
 Accordingly, Metabolex and Consultant agree as follows: 

AMENDMENT 
  

	 	1.	Term and Termination. The first sentence of Section 8 of the Consulting Agreement is hereby amended by replacing “March 31, 2013” with “June
30, 2013.” 

 Except as modified by this Fourth Amendment, all terms of the Consulting Agreement remain unchanged, in
full force and effect, and binding upon the parties hereto. 
 This Fourth Amendment may be executed in one or more counterparts, each of which
shall be deemed an original, but all of which together will constitute one and the same instrument. Facsimile and PDF signatures have the same effect as original signatures. 
 The parties are signing this Fourth Amendment on the Fourth Amendment Effective Date. 
  

									
	Metabolex, Inc.	 		 	SNPLive, LLC
					
	By:	 	

	 		 	By:	 	

									
	 Name:
	 	Charles A. McWherter	 		 	Name:	 	Sujal Shah

									
	 Title:
	 	 SVP, Research & Preclinical Development
	 		 	Title:	 	President

 FIFTH AMENDMENT TO CONSULTING AGREEMENT 

This Fifth Amendment to the Consulting Agreement (“Fifth Amendment”) is entered into on June 27, 2013 (“Fifth Amendment
Effective Date”) by Metabolex, Inc., a Delaware corporation located at 3876 Bay Center Place, Hayward, California 94545 (“Metabolex”), and SNPLive, LLC, a company with a mailing address at 5086 Holborn Way, San
Ramon, CA 94582 (“Consultant”). 
 BACKGROUND 
 Metabolex and Consultant entered into the Consulting Agreement on June 27, 2012, which automatically terminated on September 30, 2012. Metabolex and Consultant then entered into (1) a First
Amendment to the Consulting Agreement which extended the term of the Consulting Agreement to December 31, 2012 (2) a Second Amendment to the Consulting Agreement which extended the term of the Consulting Agreement to January 31, 2013
(3) a Third Amendment to the Consulting Agreement which extended the term of the Consulting Agreement to March 31, 2013 and (4) a Fourth Amendment to the Consulting Agreement which extended the term of the Consulting Agreement to
June 30, 2013. 
 Metabolex wishes to continue working with Consultant and Consultant wishes to continue providing Services to Metabolex
under the terms of the Consulting Agreement and this Fifth Amendment. 
 Accordingly, Metabolex and Consultant agree as follows: 

AMENDMENT 
  

	 	1.	Term and Termination. The first sentence of Section 8 of the Consulting Agreement is hereby amended by replacing “June 30, 2013” with
“September 30, 2013.” 

 Except as modified by this Fifth Amendment, all terms of the Consulting Agreement remain
unchanged, in full force and effect, and binding upon the parties hereto. 
 This Fifth Amendment may be executed in one or more counterparts,
each of which shall be deemed an original, but all of which together will constitute one and the same instrument. Facsimile and PDF signatures have the same effect as original signatures. 
 The parties are signing this Fifth Amendment on the Fifth Amendment Effective Date. 
  

									
	Metabolex, Inc.	 		 	SNPLive, LLC
					
	By:	 	

	 		 	By:	 	

									
	 Name:
	 	Charles A. McWherter	 		 	Name:	 	Sujal Shah

									
	 Title:
	 	SVP, Research & Preclinical Development	 		 	Title:	 	PresidentEX-10.23

 Exhibit 10.23 

 
 

 
 October 03, 2011 
 Dr. Raymond Urbanski 
 11 North Pocono Road 

Mountain Lakes, NJ 07046 
 Dear Ray: 

Metabolex, Inc. (the “Company”) is pleased to offer you employment as Chief Medical Officer on the following terms: 

1. Position, Duties and Responsibilities. Subject to the terms set forth herein, the Company agrees to employ you in the position
of Chief Medical Officer and you hereby accept such employment effective as of a mutually acceptable start date. As Chief Medical Officer, you will report to the Company’s Chief Executive Officer (“CEO”), and will perform the duties
customarily associated with this position and such other duties as are assigned to you by the CEO. You shall devote your full business time and attention to the business affairs of the Company, except for reasonable vacations and periods of illness
or incapacity permitted by the Company’s general employment policies. The employment relationship between you and the Company shall also be governed by the general employment policies and practices of the Company, including those relating to
protection of confidential information and assignment of inventions, except that when the terms of this letter agreement differ from or are in conflict with the Company’s general employment policies or practices, this letter agreement shall
control. 
 2. Compensation and Employee Benefits. 

2.1 Base Salary. Your base salary will be three hundred forty thousand dollars ($340,000) on an annualized basis, less payroll
deductions and required withholdings, paid according to the Company’s regular payroll schedule and procedures. Your base salary may be modified by the Company in its sole discretion. For your initial year of employment, any merit increase you
receive will be pro rated for the time period for which you were employed by the Company during the calendar year. 

2.2 Hiring Bonus. You will receive a forty thousand dollar ($40,000) hiring bonus (the “Hiring Bonus”) less payroll
deductions and required withholdings, paid in two equal twenty thousand ($20,000) installments. The first twenty thousand dollar ($20,000) installment will be paid on the first regular pay date after the date upon which you commence your employment
(your “Employment Commencement Date”), provided that you present proof of your identity and work authorization, for immigration compliance purposes. The second and final twenty thousand dollar ($20,000) installment will be paid on the
one-year anniversary of your employment with the Company, provided that you remain an active full-time employee through the one-year anniversary of the Employment Commencement Date. The Hiring Bonus shall be repaid to the Company, pro rata, if
within two (2) years of your Employment Commencement Date your employment with the Company (and its successors) is terminated either (i) by you or (ii) by the Company for Cause (as defined in Section 7.2(b)). The pro rata
repayment will be the product of (i) the Hiring Bonus and (ii) the fraction where the 

  
  

Metabolex, Inc.        3876 Bay Center Place, Hayward, CA
94545        Phone: (510) 293-8800        www.metabolex.com 

 
numerator is the number of full months remaining in the two (2) year period on the date of termination and the denominator is twenty-four (24). The Hiring Bonus will not become fully earned
and vested unless you remain an active full-time employee through the second anniversary of the Employment Commencement Date. 

2.3 Housing Assistance. You are entitled to relocation assistance in accordance with the Company’s relocation expense policy
(attached as Exhibit A). 
 2.4 Discretionary Bonus. You will be eligible to participate in the Company’s annual
bonus program in recognition of your performance and achievement of agreed upon goals. Your target annual bonus will be equal to twenty-five percent (25%) of your annual base salary. Your actual bonus, if any, will be determined by the
Company’s Board of Directors (“Board”), or a subcommittee thereof, in its sole discretion, based upon its evaluation of your performance, the Company’s performance, and any other considerations it deems relevant. For your initial
year of employment, your bonus will be pro rated for the time elapsed in the bonus period for which you were employed by the Company. You must be employed through the bonus payment date in order to be eligible to earn any such bonus. Any
bonus payment shall be subject to payroll deductions and required withholdings. 
 2.5 Employee Benefits. You shall be
entitled to all employee benefits, including vacation accrual of twenty (20) days per year and health and disability benefits, for which you are eligible under the terms and conditions of the standard Company benefit plans, which may be in
effect from time to time and provided by the Company to its senior executive-level employees generally. Currently, such benefits include twelve (12) paid holidays per year, as well as paid sick leave of up to ten (10) days per year.
Notwithstanding the foregoing, the Company reserves the right to adopt, amend or discontinue any employee benefit plan or policy, including changes required by applicable law. 
 2.6 Stock Option. Subject to the approval of the Board you will be granted a stock option to purchase six hundred fifty thousand (650,000) shares of Company common stock, at a per share
exercise price equal to the per share fair market value of the common stock on the date of grant, as determined by the Board, pursuant to the Company’s equity incentive plan. Option grants are made at regular Board meetings held approximately
once each calendar quarter. Your option grant will be considered at the first regular Board meeting following your Employment Commencement Date. The term of such stock option will be ten (10) years, subject to earlier expiration in the event of
the termination of your service with the Company. You may elect to receive such stock option with an early exercise feature, wherein such stock option will be immediately exercisable, but any shares purchased prior to vesting shall be subject to
repurchase by the Company in the event that your service with the Company terminates before you become vested in the shares, at the lower of (1) the original exercise price or (2) the then-fair market value of the Company’s common
stock. You may also elect to receive your stock option without this early exercise feature. You will be vested in, and the Company’s repurchase right, if applicable, shall not apply as to, twenty-five percent (25%) of the shares covered by
the option on the first year anniversary of your Employment Commencement Date and the remaining seventy-five percent (75%) of the shares covered by the option will vest in thirty-six (36) equal monthly installments with the first monthly
installment vesting one month following the first year anniversary of your Employment Commencement Date, as long as you remain in continuous service with the Company. Notwithstanding the foregoing, a portion of the shares subject to your outstanding
stock options may vest on an accelerated basis pursuant to Sections 7 or 8. Except as provided herein, such stock options will be subject to the provisions of the equity incentive plan of the Company under which the options are granted and the
applicable form of stock option agreement thereunder (the “Plan Documents”). 
 3. Other Activities During
Employment. 
 3.1 Activities. Except with the prior written consent of the CEO, you will not, during your employment
with the Company, undertake or engage in any other employment, occupation or business enterprise, other than ones in which you are a passive investor. You may engage in civic and not-for-profit activities so long as such activities do not interfere
with the performance of your job duties. 

  

	
	www.metabolex.com
	
	2

 3.2 Investments and Interests. Except as permitted by Section 3.1 and by
Section 3.3, during your employment you agree not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by you to be adverse or antagonistic to the Company, or its business or prospects,
financial or otherwise. 
 3.3 Noncompetition. During the term of your employment by the Company, except on behalf of the
Company, you will not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have
any business connection with any other person, corporation, firm, partnership or other entity whatsoever that competes with the Company anywhere in the world, in any line of business engaged in (or planned to be engaged in) by the Company;
provided, however, that anything above to the contrary notwithstanding, you may own, as a passive investor, securities of any entity, so long as your direct holdings in any one such corporation do not in the aggregate constitute more than one
percent (1%) of the voting stock of such corporation. 
 4. Company Policies; Confidential Information and Inventions
Agreement. You acknowledge your obligations under the Company’s Employee Agreement on Confidential Information and Inventions, a copy of which is attached as Exhibit B. You further acknowledge your obligation to abide by the Company’s
rules, policies and procedures. 
 5. Immigration. Your employment is contingent upon your providing adequate
documentation to prove both your identity and authorization to work in the Untied States. 
 6. Your Representations and
Warranties. 
 6.1 No Breach of Contract. You represent and warrant that the execution and delivery of this letter
agreement by you and the performance of your obligations hereunder will not conflict with or breach any agreement, order or decree to which you are a party or by which you are bound. You warrant that you are subject to no employment agreement or
restrictive covenant preventing full performance of your duties under this letter agreement. 
 6.2 No Conflict of Interest.
You warrant that you are not, to the best of your knowledge and belief, involved in any situation that might create, or appear to create, a conflict of interest with your loyalty to or duties for the Company. 

6.3 Notification of Materials or Documents from Other Employers. You further warrant that you have not brought and will not bring
to the Company or use in the performance of your responsibilities at the Company any materials or documents of a former employer that are not generally available to the public, unless you have obtained express written authorization from the former
employer for their possession and use. 
 6.4 Notification of Other Post-Employment Obligations. You also understand
that, as part of your employment with the Company, you are not to breach any obligation of confidentiality that you have to former employers, and you agree to honor all such obligations to former employers during your employment with the Company.

 7. Termination of Employment. 
 7.1 At-Will Employment Relationship. Your employment with the Company shall be at-will. Either you or the Company may terminate the employment relationship at any time, with or without Cause and
with or without advance notice. 

  

	
	www.metabolex.com
	
	3

 7.2 Termination for Cause. 

(a) If the Company terminates your employment at any time for Cause (as defined below), your salary shall cease on the date of
termination and you shall not be entitled to severance pay, COBRA premium payments, pay in lieu of notice or any other such compensation other than payment of accrued salary and vacation and such other benefits as expressly required in such event by
applicable law or the terms of applicable benefit plans. The continued vesting of any compensatory equity award held by you shall cease on your employment termination date, and your right to exercise vested option shares shall be governed by the
Plan Documents. 
 (b) Definition of Cause. For purposes of this agreement, “Cause” means the occurrence of
any one or more of the following: (i) your conviction of, or plea of no contest with respect to, any felony or any crime involving fraud, dishonesty or moral turpitude; (ii) your participation in a fraud or act of dishonesty that results
in material harm to the Company; (iii) your intentional material violation of any contract or agreement between you and the Company, including but not limited to this letter agreement or your Employee Agreement on Confidential Information and
Inventions, or your violation of any statutory duty that you owe to the Company, but only if you do not correct such violation within thirty (30) days after written notice thereof has been provided to you; or (iv) your gross negligence or
willful neglect of your job duties, as determined by the Board in good faith, but only if you do not correct such violation within thirty (30) days after written notice thereof has been provided to you. 

  

	
	www.metabolex.com
	
	4

 7.3 Severance Benefits For Termination Without Cause or Resignation for Good
Reason. 
 (a) If the Company terminates your employment without Cause and other than as a result of your death
or disability, or if you resign your employment for Good Reason (defined below), you will be eligible to receive the severance benefits described in this Section 7.3. You will be eligible to receive, subject to payroll deductions and required
withholdings and net of any amounts earned by you pursuant to any employment or consulting arrangements obtained by you following such termination (other than the activities described in the last sentence of Section 3.1), continuation for
twelve (12) months of the greater of (i) your base salary in effect as of such termination date or (ii) your base salary as set forth in Section 2.1. In addition you will be eligible to receive your potential annual discretionary
bonus amount set forth in Section 2.4, determined as if all performance targets established by the Board have been satisfied, pro-rated for the number of months elapsed in the year in which your employment terminates. You agree to notify the
Company promptly of any amount earned by you from other employment or a consulting engagement while you are receiving severance payments under this letter agreement. Moreover, if you timely elect and remain eligible for continued coverage of your
group health insurance under COBRA, the Company will pay your premiums for COBRA coverage for up to twelve (12) months following the termination date, provided that such payments shall cease if you obtain full-time employment, or cease to be
eligible for COBRA, within such period. You agree to notify the Company promptly if you obtain full-time employment while the Company is paying your COBRA premiums under this letter agreement. Upon such termination, the vesting of all compensatory
equity awards held by you shall be accelerated such that the awards are fully vested and exercisable upon the termination date. Your receipt of any severance benefits under this Section 7.3 is contingent upon your signing and making effective a
full, general release of all claims against the Company in a form acceptable to the Company containing the language set forth in the Release Agreement attached as Exhibit C on or after the termination date. This base salary and bonus severance will
be paid in substantially equal installments over the twelve (12) month period following the termination date according to the Company’s payroll procedures; provided, however, that no payments will be made to you prior to the Effective Date
as defined in the Release Agreement. On the first payroll pay day occurring at least three (3) business days following the Effective Date, the Company will pay you the cash severance amounts you would have received on or prior to such date in a
lump sum, with the balance of the cash payments being made as originally scheduled. 
 (b) Definition of Good Reason.
For purposes of this letter agreement, “Good Reason” shall mean any one of the following events that occurs without your consent: (i) the material reduction in your responsibilities, authorities or functions as an employee of the
Company (but not merely a change in reporting relationships); (ii) a material reduction in your level of compensation your base salary and target bonuses under any corporate-performance based bonus or incentive programs); (iii) a
relocation of your place of employment that results in an increase to your round trip commute of more than twenty (20) miles; or (iv) the Company’s material breach of this letter agreement. Notwithstanding the foregoing, you must
provide written notice to the General Counsel of the Company within thirty (30) days after the date on which such event first occurs, and allow the Company thirty (30) days thereafter (the “Cure Period”) during which the Company
may attempt to rescind or correct the matter giving rise to Good Reason. If the Company does not rescind or correct the conduct giving rise to Good Reason to your reasonable satisfaction by the expiration of the Cure Period, your employment will
then terminate with Good Reason as of such thirtieth day. 

  

	
	www.metabolex.com
	
	5

 7.4 Voluntary or Mutual Termination; Death; Disability. 

(a) You may voluntarily terminate your employment with the Company at any time without Good Reason. If you terminate without Good
Reason or if your employment terminates as a result of your death or disability, your salary shall cease on the date of termination and you shall not be entitled to severance, pay in lieu of notice or any other such compensation other than payment
of accrued salary and vacation and such other benefits as expressly required in such event by applicable law or the terms of applicable benefit plans. The continued vesting of any compensatory equity awards held by you shall cease on the termination
date, and your right to exercise vested awards (or be issued shares under such vested awards) shall be governed by the terms of the Company’s applicable compensatory equity plans and the corresponding award agreements. 

(b) If at any time during the course of this letter agreement the parties by mutual consent decide to terminate this letter
agreement, you and the Company shall do so by separate agreement setting forth the terms and conditions of such termination. 

7.5 Application of Section 409A. If the Company (or, if applicable, the successor entity thereto) determines that the
severance payments and benefits provided for in this letter agreement (the “Agreement Payments”) constitute “deferred compensation” under Section 409A of the Internal Revenue Code (together, with any state law of similar
effect, “Section 409A”) and you are a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) (a “Specified Employee”), then, solely to the extent
necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Agreement Payments shall be delayed as follows: on the earliest to occur of (i) the date that is six months and one day after
the termination date or (ii) the date of your death (such earliest date, the “Delayed Initial Payment Date”), the Company (or the successor entity thereto, as applicable) shall (A) pay to you a lump sum amount equal to the sum of
the Agreement Payments that you would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the Agreement Payments had not been delayed pursuant to this Section 7.5 and (B) commence paying
the balance of the Agreement Payments in accordance with the applicable payment schedules set forth in this letter agreement. For the avoidance of doubt, it is intended that (1) each installment of the Agreement Payments provided in this letter
agreement is a separate “payment” for purposes of Section 409A, (2) all Agreement Payments satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under of Treasury Regulation
1.409A-l(b)(4) and 1.409A-l(b)(9)(iii), and (3) the Agreement Payments consisting of COBRA premiums also satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation
1.409A-l(b)(9)(v). 
 8. Change in Control. 
 8.1 Definitions. 
 (a) “Change in Control” shall mean an
Ownership Change Event (as defined below) or a series of related Ownership Change Events (collectively, a “Transaction”) wherein the stockholders of the Company immediately before the Transaction do not retain direct or indirect beneficial
ownership of more than fifty percent (50%) of the total combined voting power of the outstanding securities of the Company or, in the case of a Transaction described in Section 8.1(b)(iii), the corporation or other business entity to which
the assets of the Company were transferred (the “Transferee”), as the case may be. For purposes of the preceding sentence, indirect beneficial ownership shall include, without limitation, an interest resulting from ownership of the voting
securities of one or more corporations or other business entities that own the Company or the Transferee, as the case may be, either directly or through one or more subsidiary corporations or other business entities. 

(b) An “Ownership Change Event” shall be deemed to have occurred if any of the following occurs with respect to the
Company: (i) the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of more than fifty percent (50%) of the voting stock of the Company; (ii) a merger or consolidation
in which the Company is a party; or (iii) the sale, exchange or transfer of all or substantially all of the assets of the Company. 

  

	
	www.metabolex.com
	
	6

 8.2 Stock Awards. At the closing of a Change in Control, your outstanding
compensatory equity awards shall become vested and exercisable with respect to fifty percent (50%) of your then-unvested shares of the Company’s common stock subject thereto. In addition, in the event that within twelve (12) months
following a Change in Control, the Company terminates your employment without Cause (as defined above) and other than as a result of your death or disability, or you resign for Good Reason (as defined above) (a “Change in Control
Termination”), any remaining unvested portion of all compensatory equity awards held by you shall have the vesting accelerated such that all awards are fully vested and exercisable as of the date of the Change in Control Termination (the
“Acceleration”). As a precondition of receiving the Acceleration, you must first sign and make effective on or after the termination date a full, general release of claims in favor of the Company within forty-five (45) days after the
termination date in a form acceptable to the Company containing the language set forth in the Release Agreement attached hereto as Exhibit C. 
 8.3 Parachute Payments After the Listing Date. 
 (a) After the
Listing Date (as defined below), if any payment or distribution in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to you or for your benefit, whether under this letter agreement or otherwise (a
“Payment”), would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”) (together with any interest or penalties imposed with respect to such excise tax, the
“Excise Tax”), then you will be entitled to receive from the Company an additional payment (the “Gross-Up Payment”) in an amount equal to (i) all Excise Taxes (including any interest or penalties imposed with respect to such
taxes) on the Payment (the “First Reimbursement Payment”), (ii) all federal, state and local income taxes and employment taxes on the First Reimbursement Payment, and (iii) all Excise Taxes (including any interest or penalties
imposed with respect to such taxes) on the First Reimbursement Payment. For purposes of this provision, the term “Listing Date” means the date of the sale of the Company’s securities to the general public pursuant to an initial public
offering under a Registration Statement filed with and declared effective by the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended. 
 (b) All determinations required to be made under this Section 8.3 including whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be
utilized in arriving at such determination, shall be made by the nationally recognized certified public tax accounting firm used by the Company or, if such firm declines to serve, such other nationally recognized certified public tax accounting firm
as you may designate (the “Accounting Firm”). The Accounting Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good-faith interpretations concerning the application of Sections
280G and 4999 of the Code. The Accounting Firm shall provide its calculations, together with detailed supporting documentation, to the Company and you within thirty (30) calendar days after the date on which your right to a Payment is triggered
(if requested at that time by the Company or you) and/or at such other times as requested by the Company or you. If the Accounting Firm determines that no Excise Tax is payable with respect to a Payment, it shall furnish the Company and you with an
opinion reasonably acceptable to you that no Excise Tax will be imposed with respect to such Payment. If the Accounting Firm determines that an Excise Tax is payable with respect to a Payment, it shall furnish to the Company and you an opinion
reasonably acceptable to you of the amount of Excise Tax payable with respect to the Payments and the amount of Gross-Up Payment due to you. The Company will pay the Gross-Up Payment to you within thirty (30) days of the date the Company
receives the Accounting Firm’s opinion, but in no event later than the end of your tax year following your tax year in which you pay the Excise Tax. The Company shall bear all reasonable expenses with respect to the determinations by the
Accounting Firm required to be made hereunder. Any determination by the Accounting Firm shall be binding upon the Company and you. 

  

	
	www.metabolex.com
	
	7

 9. General Provisions. 

9.1 Severability. Whenever possible, each provision of this letter agreement will be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this letter agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will
not affect any other provision or any other jurisdiction, but such invalid, illegal or unenforceable provision will be reformed, construed and enforced in such jurisdiction so as to render it valid, legal, and enforceable consistent with the intent
of the parties insofar as possible. 
 9.2 Notices. Any notices provided hereunder must be in writing and shall be deemed
effective upon the earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight courier, to the Company at its primary office location and to you at your address as listed on the Company payroll.

 9.3 Waiver. If either party should waive any breach of any provisions of this letter agreement, you or the Company
shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this letter agreement. 
 9.4 Entire Agreement. This letter agreement, together with its exhibits, constitutes the entire and exclusive agreement between you and the Company, and it supersedes any prior agreement, promise,
representation, or statement, written or otherwise, between you and the Company with regard to this subject matter. It is entered into without reliance on any promise, representation, statement or agreement other than those expressly contained or
incorporated herein, and it cannot be modified or amended except in a writing signed by you and a duly authorized officer of the Company. 
 9.5 Counterparts. This letter agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will
constitute one and the same letter agreement. 
 9.6 Headings. The headings of the sections hereof are inserted for
convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof. 
 9.7 Successors and
Assigns. This letter agreement is intended to bind and inure to the benefit of and be enforceable by you, the Company and your and its respective successors, assigns, heirs, executors and administrators, except that you may not assign any of
your duties hereunder and you may not assign any of your rights hereunder without the written consent of the Company. 
 9.8
Governing Law. All questions concerning the construction, validity and interpretation of this letter agreement will be governed by the law of the State of California as applied to contracts made and to be performed entirely within California.

 9.9 Attorneys’ Fees. If either party hereto brings any action to enforce your or its rights hereunder, the
prevailing party in such action shall be entitled to be paid by the other party such prevailing party’s reasonable attorneys’ fees and costs incurred in such action. 
 Enclosed is your Employee Agreement on Confidential Information and Inventions, which you should read carefully. 

  

	
	www.metabolex.com
	
	8

 To indicate your acceptance of the Company’s offer, please sign this letter agreement in the space
provided below and return it to me along with the signed Employee Agreement on Confidential Information and Inventions, in the stamped self-addressed envelope, which is enclosed. This offer shall expire on October 11, 2011 if not accepted prior
to such date. If you have any questions regarding this letter agreement, feel free to contact me. 
 Sincerely, 

 

			
	METABOLEX, INC.
		
	By:	 	

		 	Harold Van Wart
		 	Chief Executive Officer

  

			
	Accepted and agreed:	 	
		
	

	 	        October 5, 2011
	Raymond W. Urbanski, M.D., Ph.D.	 	

 EXHIBIT A – Relocation Expense Policy for New and Transferred Employees 

EXHIBIT B – Employee Agreement on Confidential Information and Inventions 

EXHIBIT C – Release Agreement 

 EXHIBIT A 

RELOCATION EXPENSE POLICY FOR NEW AND TRANSFERRED EMPLOYEES 

  

	
	www.metabolex.com
	

 EXHIBIT B 

EMPLOYEE AGREEMENT ON CONFIDENTIAL INFORMATION AND INVENTIONS 

  

	
	www.metabolex.com
	
	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]